Table 1 Baseline characteristics, the mean ± SD [Range] of duration of treatment and number of injections of Ranibizumab and Aflibercept
Age (years) Median (range) | 83 (52–90) |
Gender (Male: Female) | 16:34 |
Duration of treatment in months | |
Treatment with Ranibizumab before switch to Aflibercept | 13.2 ± 4 [3–50] |
Treatment with Aflibercept after switch | 22 ± 1.2 [6–30] |
Treatment from first Ranibizumab to last follow up | 35.3 ± 5.20 [12.7–58.3] |
Number of injections | |
Ranibizumab before switch to Aflibercept | 7.8 ± 4.2 [3–21] |
Aflibercept following switch | 11.84 ± 9.9 [3–19] |